Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

Description

The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.

Official source

Eligible beneficiaries

• Private institutions of higher education
• Independent school districts
• Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
• Public and State controlled institutions of higher education
• Small businesses
• State governments
• County governments
• Native American tribal organizations (other than Federally recognized tribal governments)
• Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
• Special district governments
• Native American tribal governments (Federally recognized)
• Others (see text field entitled "Additional Information on Eligibility" for clarification)
• Public housing authorities/Indian housing authorities
• For profit organizations other than small businesses
• City or township governments